Analysts Anticipate Protagonist Therapeutics Inc (PTGX) Will Post Quarterly Sales of $18.65 Million

Share on StockTwits

Brokerages expect Protagonist Therapeutics Inc (NASDAQ:PTGX) to report sales of $18.65 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Protagonist Therapeutics’ earnings. The lowest sales estimate is $9.50 million and the highest is $27.80 million. Protagonist Therapeutics posted sales of $11.28 million during the same quarter last year, which would indicate a positive year over year growth rate of 65.3%. The business is scheduled to issue its next earnings report on Wednesday, March 6th.

According to Zacks, analysts expect that Protagonist Therapeutics will report full-year sales of $47.43 million for the current financial year, with estimates ranging from $39.96 million to $54.90 million. For the next year, analysts anticipate that the firm will report sales of $28.15 million, with estimates ranging from $12.50 million to $43.80 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Protagonist Therapeutics.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). Protagonist Therapeutics had a negative return on equity of 24.59% and a negative net margin of 70.54%. The firm had revenue of $6.12 million during the quarter, compared to analysts’ expectations of $6.35 million.

PTGX has been the subject of a number of research analyst reports. Leerink Swann lifted their target price on shares of Protagonist Therapeutics from $13.00 to $21.00 and gave the stock an “outperform” rating in a research report on Monday, August 6th. ValuEngine raised shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. Protagonist Therapeutics currently has an average rating of “Hold” and an average target price of $22.00.

Large investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC grew its position in Protagonist Therapeutics by 255.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 11,593 shares of the company’s stock worth $100,000 after purchasing an additional 8,327 shares during the period. Bank of America Corp DE grew its position in Protagonist Therapeutics by 2,262.7% in the 2nd quarter. Bank of America Corp DE now owns 21,217 shares of the company’s stock worth $143,000 after purchasing an additional 20,319 shares during the period. LMR Partners LLP bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at $210,000. Schwab Charles Investment Management Inc. grew its position in shares of Protagonist Therapeutics by 67.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 32,315 shares of the company’s stock valued at $278,000 after acquiring an additional 13,015 shares during the period. Finally, Eqis Capital Management Inc. bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at $236,000. 57.34% of the stock is owned by institutional investors and hedge funds.

NASDAQ:PTGX opened at $9.27 on Friday. Protagonist Therapeutics has a 12 month low of $5.50 and a 12 month high of $23.97. The company has a market capitalization of $209.30 million, a price-to-earnings ratio of -4.44 and a beta of 3.44.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.

Further Reading: What are the reasons investors use put options?

Get a free copy of the Zacks research report on Protagonist Therapeutics (PTGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply